Byhealth 관리

관리 기준 확인 2/4

Byhealth CEO는 Zhicheng Lin, Sep2014 에 임명되었습니다 의 임기는 10.17 년입니다. 는 CN¥ 4.34M 가치에 해당하는 회사 주식의 0.021% 직접 소유합니다. 4.34M. 경영진과 이사회의 평균 재임 기간은 각각 10.2 년과 5.4 년입니다.

주요 정보

Zhicheng Lin

최고 경영자

CN¥7.0m

총 보상

CEO 급여 비율	n/a
CEO 임기	10.2yrs
CEO 소유권	0.02%
경영진 평균 재임 기간	10.2yrs
이사회 평균 재임 기간	5.4yrs

최근 관리 업데이트

Recent updates

Byhealth Co., Ltd (SZSE:300146) Surges 32% Yet Its Low P/E Is No Reason For Excitement

Sep 30

Byhealth Co., Ltd (SZSE:300146) Just Reported Earnings, And Analysts Cut Their Target Price

Mar 23

CEO

Zhicheng Lin (56 yo)

10.2yrs

테뉴어

CN¥7,000,300

보상

Mr. Zhicheng Lin has been Chief Executive Officer at Byhealth Co.,Ltd since September 26, 2014 and served as its Vice President and Secretary since June 2012 and since July 2012 respectively. Mr. Lin was D...

리더십 팀

이름	위치	테뉴어	보상	소유권
Zhicheng Lin	CEO & Non-Independent Director	10.2yrs	CN¥7.00m	0.021% CN¥ 4.3m
Jinyin Tang	Secretary to the Board of Directors	6.6yrs	CN¥1.04m	데이터 없음
Hong Chen	Deputy General Manager	16.2yrs	CN¥5.00m	1.05% CN¥ 220.3m
Liangping Cai	Deputy General Manager	10.2yrs	CN¥5.00m	0.032% CN¥ 6.6m

10.2yrs

평균 재임 기간

53yo

평균 연령

경험이 풍부한 관리: 300146 의 관리팀은 노련하고 경험 (평균 재직 기간 10.2 년)입니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Zhicheng Lin	CEO & Non-Independent Director	10.2yrs	CN¥7.00m	0.021% CN¥ 4.3m
Shuisheng Liang	Non-Independent Vice Chairman	16.2yrs	CN¥5.00m	1.02% CN¥ 213.7m
Yunchao Liang	Non-Independent Chairman of the Board	16.2yrs	CN¥604.40k	42.17% CN¥ 8.8b
Yu Ming Hu	Independent Director	1.3yrs	CN¥42.60k	데이터 없음
Hui Tang	Non-Independent Director	16.2yrs	CN¥8.26m	0.43% CN¥ 89.2m
Heng Liu	Independent Director	1.3yrs	CN¥42.60k	데이터 없음
Zhuoyi Wu	Chairman of the Supervisory Board	1.3yrs	CN¥910.90k	데이터 없음
Huizhen Shi	Member of Supervisory Board	6.7yrs	데이터 없음	데이터 없음
Chuanyuan Deng	Independent Director	4.2yrs	CN¥120.00k	데이터 없음
Le Li	Supervisor	2.8yrs	데이터 없음	데이터 없음

5.4yrs

평균 재임 기간

56yo

평균 연령

경험이 풍부한 이사회: 300146 의 이사회는 경험(평균 재직 기간 5.4 년)으로 간주됩니다.

Byhealth 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

Byhealth Co., Ltd, Annual General Meeting, Apr 11, 2024

High number of new directors

Byhealth Co. Ltd. Approves Executive Appointments

By-health Co., Ltd., Annual General Meeting, Mar 26, 2021

By-health Co., Ltd. Announces Management Appointment

Recent updates

Consensus revenue estimates fall by 15%

Third quarter 2024 earnings released: CN¥0.013 loss per share (vs CN¥0.21 profit in 3Q 2023)

Investor sentiment deteriorates as stock falls 20%

Byhealth Co., Ltd (SZSE:300146) Surges 32% Yet Its Low P/E Is No Reason For Excitement

Byhealth Co., Ltd to Report Q3, 2024 Results on Oct 26, 2024

Investor sentiment improves as stock rises 17%

Byhealth (SZSE:300146) Will Want To Turn Around Its Return Trends

Consensus revenue estimates fall by 18%

Things Look Grim For Byhealth Co., Ltd (SZSE:300146) After Today's Downgrade

Price target decreased by 10% to CN¥19.91

New minor risk - Earnings quality

Second quarter 2024 earnings released: EPS: CN¥0.095 (vs CN¥0.30 in 2Q 2023)

Investors Don't See Light At End Of Byhealth Co., Ltd's (SZSE:300146) Tunnel

Byhealth Co., Ltd to Report First Half, 2024 Results on Aug 06, 2024

Byhealth (SZSE:300146) Could Be Struggling To Allocate Capital

First quarter 2024 earnings released: EPS: CN¥0.43 (vs CN¥0.61 in 1Q 2023)

Byhealth Co., Ltd Approves Cash Dividend for the Year 2023

Byhealth Co., Ltd to Report Q1, 2024 Results on Apr 26, 2024

We Think That There Are Issues Underlying Byhealth's (SZSE:300146) Earnings

Byhealth Co., Ltd (SZSE:300146) Just Reported Earnings, And Analysts Cut Their Target Price

Byhealth Co., Ltd Announces Profit Distribution Proposal for 2023

Byhealth Co., Ltd, Annual General Meeting, Apr 11, 2024

Price target decreased by 8.9% to CN¥24.05

Full year 2023 earnings released: EPS: CN¥1.03 (vs CN¥0.82 in FY 2022)

Now 21% overvalued

Byhealth Co., Ltd to Report Fiscal Year 2023 Results on Mar 19, 2024

Price target decreased by 7.7% to CN¥26.37

Third quarter 2023 earnings released: EPS: CN¥0.21 (vs CN¥0.25 in 3Q 2022)

Provexis plc Announces Byhealth Co., Ltd Regulatory Filing with Chinese SAMR

High number of new directors

Byhealth Co. Ltd. Approves Executive Appointments

Second quarter 2023 earnings released: EPS: CN¥0.30 (vs CN¥0.23 in 2Q 2022)

Byhealth Co., Ltd to Report First Half, 2023 Results on Aug 05, 2023

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Price target increased to CN¥27.71

Third quarter 2022 earnings released: EPS: CN¥0.25 (vs CN¥0.17 in 3Q 2021)

Consensus EPS estimates fall by 14%

Price target decreased to CN¥29.08

Second quarter 2022 earnings released

First quarter 2022 earnings: EPS and revenues exceed analyst expectations

By-Health Co., Ltd. Implements Cash Dividend for 2021, Payable on 13 April 2022

By-Health Co., Ltd. Approves Cash Dividend for 2021

By-health Co., Ltd. Proposes Cash Dividend for 2021

Full year 2021 earnings: EPS exceeds analyst expectations

Price target decreased to CN¥32.67

Price target decreased to CN¥33.98

Third quarter 2021 earnings released: EPS CN¥0.17 (vs CN¥0.32 in 3Q 2020)

Investor sentiment deteriorated over the past week

Price target increased to CN¥36.49

Price target increased to CN¥34.07

First quarter 2021 earnings released: EPS CN¥0.52 (vs CN¥0.34 in 1Q 2020)

Investor sentiment improved over the past week

By-health Co., Ltd., Annual General Meeting, Mar 26, 2021

New 90-day high: CN¥28.08

Full year 2020 earnings released: EPS CN¥0.96 (vs CN¥0.24 loss in FY 2019)

Earnings beat expectations, revenue disappoints

Price target raised to CN¥31.56

New 90-day low: CN¥22.89

By-health Co., Ltd. to Report Fiscal Year 2020 Results on Mar 06, 2021

New 90-day high: CN¥25.87

Third quarter earnings released

By-health Co., Ltd. to Report Q3, 2020 Results on Oct 28, 2020

By-health Co., Ltd. Announces Management Appointment

Price target raised to CN¥26.23

Price target raised to CN¥24.38

New 90-day high - CN¥22.58

By-health Co., Ltd. to Report First Half, 2020 Results on Jul 30, 2020

CEO

테뉴어

보상